Log In Sign up
The largest database of trusted experimental protocols

Bp0004 1

Manufactured by BioXCell
Visit Supplier
Sourced in United States

BP0004–1 is a laboratory centrifuge designed for general-purpose applications. It is capable of separating mixtures of liquids, solids, and gases based on their differences in density.

Automatically generated - may contain errors

Lab products found in correlation

Be0003 1, by BioXCell (2 mentions) Bp0090, by BioXCell (1 mentions) Bp0089, by BioXCell (1 mentions) Bp0003 1, by BioXCell (1 mentions)

3 protocols using bp0004 1

1

Immune-Related Tumor Delay Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
In order to study whether effects on primary tumor delay were immune related, in a second experiment, mice were treated with anti-CD4 and anti-CD8 antibodies (BE0003–1 and BP0004–1, BioXcell, NH, USA). Depletion of CD4+ and CD8+ T-cell subsets was done by i.p. injections at 100 μg/mouse on the 4th, 5th and 6th day after tumor inoculation and subsequently on every 6th day until sacrifice as was described by Demaria et al. [18 ].
Oei A.L., Korangath P., Mulka K., Helenius M., Coulter J.B., Stewart J., Velarde E., Crezee J., Simons B., Stalpers L.J., Kok H.P., Gabrielson K., Franken N.A, & Ivkov R. (2019). Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 36(SUP1), 47-63.
+ Open protocol
+ Expand
2

CD8 and CD4 T cell depletion

Check if the same lab product or an alternative is used in the 5 most similar protocols
For CD8 and CD4 T cell depletion, anti-CD8 (clone: 53–6.7, BioXcell # BP0004–1) and anti-CD4 (clone: GK1.5, BioXcell # BP0003–1) antibodies were i.p. injected per mouse according to the following regimen: day −1 and day 3 (500 μg), then every 72 hours until experiment endpoint (250 μg) (40 ). As a negative control to CD8 and CD4 depletion, mice from other groups received, by i.p. injection, InVivoPlus rat IgG2a isotype control, anti-trinitrophenol (clone 2A3, BioXcell #BP0089) and InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin (clone LTF-2, BioXcell # BP0090), respectively.
Wennerberg E., Mukherjee S., Spada S., Hung C., Agrusa C., Chen C., Valeta-Magara A., Rudqvist N.P., Van Nest S., Kamel M.K., Nasar A., Narula N., Mittal V., Markowitz G., Zhou X.K., Adusumilli P.S., Borczuk A., White T.E., Khan A.G., Balderes P., Lorenz I.C., Altorki N., Demaria S., McGraw T.E, & Stiles B.M. (2022). Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. Science translational medicine, 14(636), eabe8195.
+ Open protocol
+ Expand
3

Immune-Related Tumor Delay Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
In order to study whether effects on primary tumor delay were immune related, in a second experiment, mice were treated with anti-CD4 and anti-CD8 antibodies (BE0003–1 and BP0004–1, BioXcell, NH, USA). Depletion of CD4+ and CD8+ T-cell subsets was done by i.p. injections at 100 μg/mouse on the 4th, 5th and 6th day after tumor inoculation and subsequently on every 6th day until sacrifice as was described by Demaria et al. [18 ].
Oei A.L., Korangath P., Mulka K., Helenius M., Coulter J.B., Stewart J., Velarde E., Crezee J., Simons B., Stalpers L.J., Kok H.P., Gabrielson K., Franken N.A, & Ivkov R. (2019). Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 36(SUP1), 47-63.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!